Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 3-year average of 13.42%, near the low end of its 3-year range (0.00%–34.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 24.51%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
24.51%
DEBT TO ASSETS RATIO AVG 3Y
13.93%
DEBT TO ASSETS RATIO AVG 5Y
13.42%
DEBT TO ASSETS RATIO AVG 10Y
2.47%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 847 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Boundless Bio, Inc.
Market Cap
$58.66M
Debt to Assets Ratio
0.00%
TTM Avg
24.51%
3Y Avg
13.93%
5Y Avg
13.42%
Market Cap
$58.79M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$59.31M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.16M
Debt to Assets Ratio
0.50%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.04M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$56.98M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$61.12M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | $58.66M | 0.00% | 24.51% | 13.93% | 13.42% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.79M | 0.00% | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.31M | 0.01% | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.36M | 0.09% | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.16M | 0.50% | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.04M | 0.06% | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.09M | 0.00% | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | 0.00% | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.12M | 0.01% | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $61.28M | 0.04% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
9.48
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 34.25% |
| 2025-12-31 | 31.22% |
| 2025-09-30 | 29.49% |
| 2025-06-30 | 27.59% |
| 2025-03-31 | 25.40% |
| 2024-12-31 | 23.08% |
| 2024-09-30 | 0.07% |
| 2024-06-30 | 0.44% |
| 2024-03-31 | 1.30% |
| 2023-12-31 | 1.69% |
| 2023-09-30 | 3.05% |
| 2023-06-30 | 3.56% |
| 2022-12-31 | 6.75% |
| 2019-09-30 | 6.77% |
| 2019-06-30 | 6.42% |
| 2019-03-31 | 5.78% |
| 2018-12-31 | 1.50% |
| 2018-09-30 | 1.21% |
| 2018-06-30 | 1.14% |
| 2018-03-31 | 1.35% |
| 2017-12-31 | 4.02% |
| 2017-09-30 | 1.53% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 1.69% |
| 2016-12-31 | 1.94% |
| 2016-09-30 | 1.71% |
